[144] Arcutis Biotherapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Arcutis Biotherapeutics (ARQT) filed a Form 144 reporting a planned sale of 3,847 common shares to be executed through Merrill Lynch on 08/08/2025. The filing shows these shares were acquired on 08/01/2025 as a restricted stock vest from Arcutis Biotherapeutics, Inc., and lists an aggregate market value of $53,988.51 and the company’s outstanding shares as 119,201,724. The trade is slated for NASDAQ.

The filing also discloses recent sales by Patrick Burnett in the past three months: 23,000 shares on 07/10/2025 for $346,047.00, 5,750 shares on 07/14/2025 for $86,654.00, and 2,622 shares on 08/04/2025 for $37,485.69. No additional commentary or plan-adoption date is provided in the form text.

Insights

Securities Analyst

TL;DR: Routine Rule 144 sale after restricted stock vesting; recent open-market dispositions disclosed.

The Form 144 documents a proposed sale of 3,847 common shares via Merrill Lynch on 08/08/2025, acquired on 08/01/2025 through a restricted stock vesting. The filing also lists earlier open-market sales by Patrick Burnett of 23,000, 5,750 and 2,622 shares in July and early August 2025 with stated gross proceeds. From a market-impact standpoint the form records transaction details and broker routing; it does not include any company financial performance data or statements that alter the issuer’s valuation in this filing.

Corporate Governance Expert

TL;DR: Disclosure meets Rule 144 requirements; no governance red flags apparent from the form itself.

The submission identifies the nature of acquisition (restricted stock vesting) and provides required sale details including broker, dates, amounts and gross proceeds for prior sales. There is an explicit representation regarding absence of undisclosed material adverse information, but the form contains no additional governance disclosures or 10b5-1 plan adoption date. On its face the filing reflects standard insider reporting rather than an unusual governance event.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Dr. 5th Floor Columbus OH 43240	3847	53988.51	119201724	08/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/01/2025	Restricted stock vest	Arcutis Biotherapetics Inc			3847	08/08/2025	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick Burnett 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	07/10/2025	23000	346047.00
Patrick Burnett 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	07/14/2025	5750	86654.00
Patrick Burnett 3027 Townsgate Rd Ste 300, Westlake Village CA 91361	Common	08/04/2025	2622	37485.69

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ARQT Form 144 report?

The Form 144 reports a planned sale of 3,847 common shares of Arcutis (ARQT) to be executed via Merrill Lynch on 08/08/2025.

How were the 3,847 ARQT shares acquired?

The filing states the shares were acquired on 08/01/2025 as a restricted stock vest from Arcutis Biotherapeutics, Inc.

What recent ARQT sales are disclosed in the filing?

The form lists prior sales by Patrick Burnett: 23,000 shares on 07/10/2025 for $346,047.00, 5,750 shares on 07/14/2025 for $86,654.00, and 2,622 shares on 08/04/2025 for $37,485.69.

Which broker will handle the planned ARQT sale?

The planned sale of 3,847 shares is listed to be handled by Merrill Lynch (address shown in the form).

On which exchange is the ARQT sale to occur?

The filing indicates the sale is expected to occur on NASDAQ.

How many Arcutis shares are outstanding according to the filing?

The Form 144 lists 119,201,724 shares outstanding for the issuer.